A Brief Review of MicroRNA Profiling in Human Prostate Cancer Tissues and Plasma
Authors:
- Georgios KallinikasGKGeorgios Kallinikas
- Amin M. EktesabiAEAmin M. Ektesabi
- Chirag M. VaswaniChirag M. Vaswani
- Georgios HaronisGHGeorgios Haronis
- Eirini KallinikaEKEirini Kallinika
- Diomidis KozyrakisDKDiomidis Kozyrakis
- Athanasios FiliosAFAthanasios Filios
- Panagiotis FiliosPFPanagiotis Filios
- Despoina MityliniouDMDespoina Mityliniou
- Konstantinos SafioleasKSKonstantinos Safioleas
- Dimitrios BoziosDBDimitrios Bozios
Open Access
- 12 August 2025
- journal article
- review article
- Published by MDPI AG in Biomolecules
- Vol. 15 (8) , 1156
Abstract
(1) Background: The gold standard, prostate-specific antigen (PSA) screening lacks the sensitivity and specificity required for confident, early prostate-cancer detection. MicroRNAs (miRNAs) are small, highly stable, non-coding RNAs whose expression changes reproducibly in malignancy and therefore offer promise as minimally invasive biomarkers. Although prostate cancer biopsies are the gold standard for prostate cancer diagnosis, limitations in the field continue to persist. Since circulating fluids can also be a source of miRNA biomarkers, we investigated the overlap between miRNAs enriched in prostate cancer tissue and those isolated from the plasma of patients with prostate cancer. (2) Methods: We synthesized the published literature (PubMed, Google Scholar, ResearchGate, 2005–April 2025) and re-analyzed three Gene Expression Omnibus (GEO) datasets (GSE54516, GSE21032—tissue; GSE206793—plasma) to identify miRNAs consistently dysregulated in prostate cancer tissue and circulation. (3) Results: Of the 318 screened full-text articles, 24 met the inclusion criteria. From the GEO reanalysis (false-discovery-rate < 0.05, |log2FC| ≥ 1), 219 and 326 miRNAs were differentially expressed in tissue, whereas 12 were altered in plasma. Two miRNAs—miR-449b and miR-455-3p—were common in both compartments, highlighting their translational potential as liquid biopsy surrogates of tumor biology. (4) Conclusions: We summarize functional evidence for leading tumor-suppressive (e.g., miR-205, miR-23b, miR-455-3p) and oncogenic (e.g., miR-21, miR-182, miR-449b) candidates, discuss their intersection with the androgen-receptor, TGF-β, WNT/β-catenin, and PI3K-AKT signaling, and outline outstanding requirements for the clinical qualification of miRNA panels in prostate cancer.Keywords
This publication has 87 references indexed in Scilit:
- The potential of microRNAs as human prostate cancer biomarkers: A meta‐analysis of related studiesJournal of Cellular Biochemistry, 2017
- Clinical and molecular markers of long‐term survival after oligometastasis‐directed stereotactic body radiotherapy (SBRT)Cancer, 2016
- miQ—A novel microRNA based diagnostic and prognostic tool for prostate cancerInternational Journal of Cancer, 2012
- The altered expression of MiR‐221/‐222 and MiR‐23b/‐27b is associated with the development of human castration resistant prostate cancerThe Prostate, 2011
- TMPRSS2–ERG gene fusion prevalence and class are significantly different in prostate cancer of caucasian, african‐american and japanese patientsThe Prostate, 2010
- MicroRNA‐205–directed transcriptional activation of tumor suppressor genes in prostate cancerCancer, 2010
- miR‐34c is downregulated in prostate cancer and exerts tumor suppressive functionsInternational Journal of Cancer, 2010
- Diagnostic and prognostic implications of microRNA profiling in prostate carcinomaInternational Journal of Cancer, 2009
- Expression of microRNAs and protein‐coding genes associated with perineural invasion in prostate cancerThe Prostate, 2008
- Detection and analysis of ?-catenin mutations in prostate cancerThe Prostate, 2000